Outset Medical reported third-quarter revenue of $33.6 million, up 14% year-over-year, and reiterated 2026 revenue guidance of $125 million to $130 million. Non-GAAP gross margin reached 40.8%.
OM · Outset Medical, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Sep 2020 to Nov 2026
Up next
Latest documents
Outset Medical, Inc. reported quarterly revenue growth of 14% and nine-month revenue growth of 3%. Gross margin improved to 40.7% for the quarter and 41.9% for nine months, driven primarily by higher-margin service and other revenue.
Outset Medical reported third-quarter revenue of $33.6 million, up 14%, gross margin of 40.7% and net loss of $14.7 million. It reiterated 2026 revenue guidance of $125 million to $130 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Third-quarter revenue grew 14%, gross margin expanded 130 basis points, operating expenses fell 5%, and GAAP net loss narrowed; the HCA refresh agreement, estimated $150 million refresh opportunity, 96% customer retention, reiterated guidance, and potential HHS support provide commercial positives. Risks include a wider non-GAAP loss, lower product gross margin, significant cash use, potential gross-margin pressure from console mix, and uncertainty over implementation of the HHS plan.
- + Cumulative retention among parent customers that purchased Tablo consoles reached 96% since commercial launch. new
- + The HHS Kidney Care National Plan was viewed as a potential policy tailwind that could encourage broader home-dialysis adoption and new-technology adoption. new
- + Management reiterated full-year 2026 revenue guidance of $125 million to $130 million and low-40% to mid-40% non-GAAP gross-margin guidance. new
- − Non-GAAP net loss widened to $12.9 million from $12.4 million in the prior-year period. new
- − Product gross margin declined 150 basis points year-over-year to 44.2%. new
- − A higher mix of console sales could push full-year non-GAAP gross margin toward the lower end of the guidance range. new
- − The ultimate impact of the HHS Kidney Care National Plan remains dependent on implementation. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Console revenue | $10.5M | the third quarter | +25.9% |
|
|
|||
| Net cash used during the quarter | $10.3M | the third quarter | — |
|
|
|||
| Non-GAAP general and administrative expense non-GAAP | $24.18M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP gross margin non-GAAP | 42.2% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP gross profit non-GAAP | $39.28M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP net loss non-GAAP | $12.9M | the third quarter | — |
|
|
|||
| Non-GAAP net loss per share, diluted non-GAAP | -$2.32 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP net loss, diluted non-GAAP | -$43M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP research and development expense non-GAAP | $15.19M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP sales and marketing expense non-GAAP | $36.13M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP total operating expense non-GAAP | $75.5M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Recurring revenue | $23.1M | the third quarter | — |
|
|
|||
| Total cash, including restricted cash, cash equivalents and investment securities | $140.7M | As of September 30, 2026 | — |
| Total cash, including restricted cash, cash equivalents and short-term investments | $140.7M | as of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OM
this stock
Outset Medical, Inc.
|
$53.03M | -24.3% | +5.1% | — | 4.3% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 17
Outset Medical reported third-quarter revenue of $33.6 million, up 14%, gross margin of 40.7% and net loss of $14.7 million. It reiterated 2026 revenue guidance of $125 million to $130 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OM | -24.7% | -31.5% | -44.6% | -30.3% | -24.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -16.1% | -22.2% | -35.4% | -21.6% | -25.4% |